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Failure to maintain T-cell homeostasis during HIV-1
infection11-13 results in compromised immunity, allowing
development of opportunistic infections and progression to
AIDS. Loss of CD4+ T cells due to direct and indirect
mechanisms14,15 is the primary cause of this imbalance and
assessment of absolute CD4+ cell numbers in adults and CD4+
percentage is used as a clinical benchmark of disease
progression. Immunotherapeutic strategies designed to
restore homeostatic balance and immune competency have
been employed,16 although there is little evidence to suggest
that these can lead to sustainable reduction in viral burden.
Conversely, antiviral drug strategies, notably HIV protease
inhibitors (PIs), have resulted in significant suppression of viral
replication. The increased likelihood that persistent virus can
be removed with provision of antiretroviral treatment has
raised the additional consideration that T-cell immunity may
be restored, resulting in the re-establishment of T-cell
homeostasis.17 There is evidence that immune reconstitution
can occur in patients receiving HIV PIs either as
monotherapy18 or in combination with nucleoside analogues.1
There is also evidence that immune reconstitution occurs in
children after receiving ART regimens,3-5,19 where it has been
shown that children had an earlier and greater increase in
naïve T-cell subsets than adults, probably due to a more active
thymus, with the potential for immune reconstitution when
HIV-1 replication is controlled.
Evidence that ART can lead to changes in immune function
was initially shown in studies investigating improvement in
the functional capacity of T-helper cells in response to
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The vexing issue of whether the immune system can be reconstituted during HIV infection by supplying antiretroviral therapy
(ART) has been a question asked about HIV-infected adults and children receiving therapy.1-9 Knowing that the immune system
is sufficiently plastic in adults to show restoration of specific and general immunity after receiving ART is promising when
translated to paediatric treatment. There is evidence in children of immune reconstitution after receiving various therapeutic
regimens.2,10 This review will examine some of the aspects of immune restoration in general, and specifically in children, and
pose the question whether knowledge of changes in immunity in tandem with viral suppression can provide clues as to how
to measure immune efficacy of ART.
THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE                                         november 2005 43
zidovudine (ZDV) in adults20,21 and didanosine in children.22
With the advent of more powerful antiviral PIs, more
comprehensive studies have emerged showing the ability of
the immune system to demonstrate self-restorative
changes.1,18 Improvements in naïve and/or memory CD4+ and
CD8+ T-cell changes have been shown in response to ritonavir
monotherapy18 and highly active regimens consisting of either
ritonavir or indinavir in combination with nucleoside
analogues.1 The latter study focused on a group of patients
who had never been exposed to ART and provided some
evidence for immune restoration in response to removing
replicating virus. 
Studies in adults have shown that in patients who failed ART,
and switched to another course, a progressive increase in
absolute numbers of naïve and memory CD4+ cells, based on
differential L-selectin (CD62L) and CD45RA expression, was
observed over 6 months in response to highly active
antiretroviral therapy (HAART). Co-expression of L-selectin
with CD45RA detects functionally competent naïve cells
before interaction with cognate antigen.23,24 Studies in
children have shown that the ability to proliferate to
pokeweed mitogen before HAART was lower in HIV-infected
children than in a control HIV-uninfected group, but recovered
to normal levels after a year on ART. Previous studies in
children25 have found that mitogen-induced tumour necrosis
factor (TNF)-alpha and interferon (IFN)-gamma production
was lower before ART (p < 0.001), but returned to near-normal
levels after 1 year of ART.9
EVENTS OCCURRING IN LYMPH NODES
The preceding discussions have outlined that T-cell
populations show plasticity in their ability to repopulate the
peripheral circulation in response to ART.26 While it is clear
that ART can suppress plasma HIV replication sufficiently to
result in beneficial changes in peripheral T-cell immunity in
children, there is less distinct evidence of events occurring
within lymphoid compartments. Studies in adults
investigating tonsil27,28 or lymph node (LN) tissue29 in a cross-
sectional manner have shown that viral load is significantly
reduced with only rare HIV-1-infected cells existing within
lymphoid tissue after more than 2 years of treatment. Studies
that investigated LNs in a sequential manner30-32 have shown
evidence of increased proportions of naïve T-cells and
suppressed viral load after the first 2 - 3 months. Very few
studies have examined events occurring in children at the LN
level, probably because of the difficulty of taking biopsies.
In adults, one of the first events after HIV transmission
through mucosa is the ‘seeding’ of HIV to lymphoid structures,
most notably the LNs.33 In children, where transmission may
occur either in utero or in the perinatal period, ‘seeding’ of HIV
to lymphoid tissues would occur either at the time of birth or
very soon after birth. In these scenarios lymphoid structures
will be taken over by HIV prior to exposure to any other
infection. In utero infection would have catastrophic effects
on neonatally developing immunity, as bone marrow, thymus
and LNs would be infected and disrupt the ontology of T cells.
This would lead to severely compromised immunity very early
in life and may explain rapid progression to AIDS in children
infected in utero. However, as in adults, in children infected at
birth or perinatally HIV appropriates LN structures within the
microenvironment of the germinal center (GC) by displacing
antigens34 complexed with the follicular dendritic cell (FDC)
network.35 This antigen displacement is thought to curtail
immune responses to non-HIV antigens, and viral antigen
persistence additionally results in chronic stimulation leading
to destruction of the lymphoid microenvironment and
dissolution of the FDC network. Histologically this is observed
as a regression of the GC and disappearance of the FDC
network.36 As an intact LN architecture is required for clonal
expansion of effector T cells upon interaction with cognate
antigens, disintegration of the LN microenvironment therefore
impedes the development of new immune responses and leads
to susceptibility to opportunistic infections. It would be
expected that such events occurring in early life would stunt
the development of specific immunity to the plethora of
antigens and pathogens bombarding newly born children. The
sooner this situation can be reversed by suppressing viraemia
with effective ART, the better the chance of longer-term
survival. The ability to measure and find a marker of successful
immune regeneration in children would enable better
assessment of different ART regimens.
A CLOSER LOOK AT T CELLS
It is clear from the studies described in both adults and 
children that CD4+ and CD8+ T cells with both naïve and
memory phenotypes emerge during ART. Analysis of events
that occur more closely within the CD8+ T-cell compartment
is crucial from the perspective that CD8+ cells are directly
implicated in providing immunological protection. This is very
important not only with regard to formulating a marker of ART
immune efficacy, but also in developing therapeutic vaccine
strategies in tandem with ART. During HIV infection, detection
of a skewed expansion of CD8+ cells that use a limited Vß 
T-cell receptor (TCR) type have been identified in infants37 and
adults.38 This results in a limited pattern of recognition of HIV
and a probable loss of protective immunity.39 One important
aspect of investigating immune reconstitution in children is
that cells responsible for protective immunity, namely CD8+ 
T cells, can increase in numbers and possess anti-HIV
recognition. There are two ways of analysing whether CD8+ 
T cells may improve in quality after ART: (i ) by investigating
TCR expression and whether this changes in response to
suppression of viraemia; and (ii ) by investigating HIV-specific
recognition of cells and whether the number of epitopes (or
regions recognised) increases with ART. There are various ways
of investigating TCR expression – either directly using a panel
of monoclonal antibodies and flow cytometry,37,40 or by
molecular means of measuring the length of the expressed
gene that encodes for the TCR.41,42 Additionally, several
investigators have measured T-cell receptor excision circles
(TRECs), which indirectly measure thymic output of T cells.6,8,43
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Use of these differing technologies has allowed assessment of
whether there is a ‘normalisation’ of CD8+ T cells in response
to ART. 
Investigating TCR use by flow cytometry has revealed that
there was abnormally expanded CD8 TCR use at baseline,26
most notably utilising Vß12, demonstrating that clonal
dominance existed before therapy, and possibly indicating
reduced efficacy of CTL responses.44 There was a loss of
repertoire bias accompanied by drug-mediated suppression of
viral load at 8 weeks of ART. From an immunological
perspective, these data imply that newly replicating virus is
required to maintain the presence of expanded antigen-
specific CD8+ cells. In this study, it was found that the
majority of CD8+ cells expressing different TCR types was
negative for L-selectin (CD62L) and was most probably of the
memory CD45RO+ phenotype. The flattening of the TCR
repertoire in response to ART probably reflects a redistribution
of existing clones rather than development of new T cells in
the thymus. Whether these changes are any different in
children remains to be seen and may represent a useful marker
by which to gauge immune efficacy of ART. 
These data provide indirect evidence that lowering persistently
high levels of viral replication with ART can reduce the
stimulus that maintains expanded CD8+ clones. By inference,
we can postulate that changes in the phenotype of CD8+ 
T cells reflect changes in viraemia.
This notion can be explored in greater detail by measuring
anti-HIV-specific T-cell immunity, which can be achieved by
investigating the frequency of epitope-specific CD8+ cells
using peptide/major histocompatibility complex (MHC)
tetramers.45 This technique is particularly useful for exploring
the hypothesis that high levels of replicating HIV-1 are
required to maintain anti-HIV CD8+ cells. As it has been
shown functionally that a restricted anti-HIV cytotoxic 
T lymphocyte (CTL) clonal repertoire exists in infected
individuals,46,47 it is possible that a reduced clonal repertoire
during ART could potentially result in broader CD8+ T-cell
response to other antigens. Various studies using MHC
tetramers have investigated the nature of antigen-specific
cells and how they change in frequency after ART. One of the
first studies in adults showed that of 19 HIV-infected
individuals48 72%  had CD8+ cells recognising an epitope in
Gag (SLYNTVATL) and to a lesser extent in Pol (ILKEPVHGV).
When the frequency of epitope-specific cells in patients
receiving ART for the first time, was assessed, 5 of 6 showed a
significant loss of tetramer-positive CD8+ cells in parallel with
suppression of replicating HIV. This would suggest that
maintenance of HIV-1-specific clones is dependent on the
persistence of replicating virus. Reduction in cell frequency
was independent of gross CD4+ and CD8+ changes and was
not likely to be due to mutations occurring in Gag or Pol
epitopes. As most epitope-specific CD8+ T cells did not express
acute activation markers48 prior to drug therapy, loss of
circulating tetramer-stained cells in response to HAART was
unlikely to be due to a decline in the gross activated CD8+ T-
cell pool. 
Collectively, these data may reflect a situation whereby
suppression of viraemia with successful ART is proportional to
a reduction in the frequency of anti-HIV-specific CD8+ T cells.
It may be hypothesised that effective ART causes reduced
antigen persistence and hence reduces the requirement to
maintain high levels of antigen-specific CD8+ T cells. Such
dynamic changes in the immune system in tandem with viral
suppression can be exploited for an added marker of immune
efficacy to ART.
CONCLUSIONS
This review has shown that the immune system has an 
endogenous ability to respond favourably to ART, particularly
in children, in whom the number of naïve CD4+ and CD8+
T cells is high. The main point of measuring these responses is
to understand how a relatively naïve immune system in
children can respond in a dynamic fashion leading to removal
of persisting antigen, i.e. suppression of viral load with ART.
The consistent correlation between viral load and activated
CD8+ T cells in blood and LN implies that activation signals are
reduced – either indirectly (via reduction in inflammatory
cytokine levels) or directly (by diminishing antigen
engagement with T cells) as HIV replication is suppressed. This
has been the basis of several findings that have proposed that
CD38+ is a measure of immune reconstitution,49,50 where the
inverse proportionality with viral load makes this an attractive
marker. Diminished antigen load, due to suppressed viral load,
is mirrored by reductions in oligoclonally expanded CD8+ 
T cells and reduced frequencies of antigen-specific CD8+ 
T cells. The overall implications of these findings are that
immune restoration in response to ART is dependent on
significant and sustained HIV-1 suppression in lymphoid
tissue, allowing lymphoid structures to return. All these
factors provide clues as to how we can measure immune
efficacy of ART in children, which in turn has importance for
understanding the effectiveness of returning HIV-1 infected
children to a ‘normalised’ state where immune robustness can
protect against opportunistic infections. Additionally, these
observations may have significant implications for the success
of therapeutic vaccine strategies so that improved immunity,
in response to ART, can be exploited for the benefit of long-
term immune protection in HIV-infected children.
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